Major findings supporting the involvement of CB2R in psychotic disorders
|Genetic studies||Genetic manipulation||Animal specie||Experimental test||Behavioral changes||References|
|CB2–/–||Mouse, ICR||OF||↑ sensibility to cocaine-induced hyperlocomotion|||
|SDIA||short and long-term memory impairment||[44, 71]|
|Pharmacological studies||Drug||Animal specie||Experimental test||Dosis||Behavioral changes||References|
|AM630 (CB2R antagonist)||Mouse, C57BL/6J||PPI||3 and 30 mg/kg||↑ alteration induced by MK-801|||
|Mouse, ICR||OF||2 mg/kg||↑ MK-801-induced hyperlocomotion|||
|JWH015 (agonista CB2R)||Mouse, BALB/c||PPI||1, 3 and 10 mg/kg||↓ alteration induced by MK-801|||
|JWH133 (agonista CB2R)||Mouse, ICR||OF||20 mg/kg||↓ cocaine-induced hyperlocomotion|||
|Mouse, C57BL/6J||OF||10, 20 and 30 mg/kg||↓ cocaine-induced hyperlocomotion|||
|CB2R gene expression||Caucasian||↓ reduction in PBMCs|||
|rs12744386 rs2501432||Japanese||↑ incidence|||
|rs2501432||Chinese (Han ethnic group)||Allele T ↑ risk|||
|rs22229579||Allele T ↓ risk|
|rs6689530 rs34570472 Cnr2_ht1 Cnr2_ht2 Cnr2_ht3||Korean||No effect|||
OF: open field test; SDIA: step-down inhibitory avoidance; PBMCs: peripheral blood mononuclear cells
We thank all participants in this study. We greatly appreciated Biorender for helping to create figure 1.
MSGG and JM conceived the presented idea. MSGG took the lead in writing the manuscript. FN and AG wrote the manuscript in consultation with MSGG. All authors provided critical feedback and helped shape the research, analysis, and manuscript.
The authors declare no conflict of interest.
© The Author(s) 2021.